- Science & technologyScience & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
COVID-19 UPDATESNovavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
- Who we areWho we are
We are a biotechnology company committed to help address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
- Insights
Novavax’s Novel Matrix-M™ Adjuvant Technology is Key Component of Oxford Malaria Vaccine
Novavax’s Matrix-M™ adjuvant is being used in Oxford University’s R21/Matrix-M™ malaria vaccine. The malaria vaccine recently received its first authorizations in Ghana and Nigeria and was announced in a joint press release by Oxford, Serum Institute of India and Novavax.
